Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma

doi:10.1016/j.canrad.2021.01.008

HFCAS OpenIR

	Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
	Zeng, J.1,3; Cui, X.2,3,4; Cheng, L.2,3; Chen, Y.2,3; Du, X.2,3; Sheng, L.2,3
	2021-07-01
发表期刊	CANCER RADIOTHERAPIE
ISSN	1278-3218
通讯作者	Sheng, L.(m05shengliming@zju.edu.cn)
摘要	Purpose. - The aim of this study was to evaluate the efficacy of liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Patients and methods. - Seventy-nine consecutive patients treated with liposome-paclitaxel based concurrent chemoradiotherapy between January 2015 and December 2019 at Cancer hospital of the University of Chinese Academy of Sciences (Zhejiang cancer hospital) were enrolled in this study. The overall response, toxicities, progression-free survival and overall survival were analyzed with SPSS software. Results. - A total of 302 cycles of weekly chemotherapy were delivered, with a median 4 courses. After concurrent chemoradiotherapy (CCRT), the efficacy was classified as CR in 4 cases (5.1%), PR in 22 cases (28.2%) and SD in 51 cases (65.4%). The median PFS and OS time were 18.2 months and 23.4 months. The 3-year PFS and OS rates were 45.1% and 43.6%, respectively. Conclusions. - Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen. (C) 2021 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
关键词	Esophageal squamous cell carcinoma Liposome-paclitaxel Chemoradiotherapy Toxicities
DOI	10.1016/j.canrad.2021.01.008
关键词[WOS]	NEOADJUVANT CHEMORADIOTHERAPY ; RANDOMIZED-TRIAL ; PHASE-II ; CISPLATIN ; CANCER ; CHEMORADIATION ; FLUOROURACIL ; RADIOTHERAPY ; REGIMENS ; TAXANE
收录类别	SCI
语种	英语
资助项目	Nature Science Foundation of Zhejiang province
项目资助者	Nature Science Foundation of Zhejiang province
WOS研究方向	Oncology ; Radiology, Nuclear Medicine & Medical Imaging
WOS类目	Oncology ; Radiology, Nuclear Medicine & Medical Imaging
WOS记录号	WOS:000672160500005
出版者	ELSEVIER
引用统计	被引频次：1[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/123518
专题	中国科学院合肥物质科学研究院
通讯作者	Sheng, L.
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Surg, Hangzhou, Zhejiang, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Radiotherapy, 1 Banshandong Rd, Hangzhou 310022, Zhejiang, Peoples R China 3.Key Lab Diag & Treatment Technol Thorac Oncol, Hangzhou, Zhejiang, Peoples R China 4.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Zeng, J.,Cui, X.,Cheng, L.,et al. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma[J]. CANCER RADIOTHERAPIE,2021,25.
APA	Zeng, J.,Cui, X.,Cheng, L.,Chen, Y.,Du, X.,&Sheng, L..(2021).Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.CANCER RADIOTHERAPIE,25.
MLA	Zeng, J.,et al."Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma".CANCER RADIOTHERAPIE 25(2021).